Drug Profile


Alternative Names: L-FMAU; Levovir; Revovir

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bukwang
  • Developer Bukwang Pharmaceutical; Eisai Co Ltd; Pharmasset
  • Class Antivirals; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 24 Jun 2015 No recent reports on development identified - Preregistration for Hepatitis B in China (PO)
  • 01 Sep 2014 Bukwang Pharmaceutical completes a phase III trial in Hepatitis B in South Korea (NCT00672867)
  • 01 Nov 2013 Eisai receives a non-approvable letter from the Chinese regulatory authority for clevudine for the treatment of chronic hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top